SynthesisRadiation oncology (London, England)2026
Immune checkpoint inhibitors with neoadjuvant chemoradiotherapy in proficient MMR rectal cancer: systematic review and meta-analysis.
Synthesis in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the efficacy and safety of neoadjuvant chemoradiotherapy plus immune checkpoint inhibitors (CRT-ICI) for mismatch repair proficient (pMMR) locally advanced rectal cancer (LARC).
methodsFive databases were systematically searched. Pooled pathological complete response (pCR) and composite clinical response (CR) and grade 3-4 neoadjuvant-related adverse events (AEs), surgical AEs, and immune-related AEs (ir-AEs) were calculated, and comparative results (CRT-ICI vs. CRT alone) were conducted on randomized clinical trials (RCTs) via risk ratios (RRs). Also, subgroup analyses were conducted in pMMR-exclusive cohorts for all available endpoints.
resultsEighteen studies (1,619 patients) were included. The pooled pCR rate was 41% (95% CI: 36-47%) overall and in the pMMR-exclusive group (95% CI: 35-48%). Composite CR rates were 49% (95%CI: 38-60%) overall and 54% (95%CI: 41-66%) in pMMR cohorts. Analysis of comparative RCTs showed CRT-ICI significantly improved both pCR (RR 1.7, 95%CI:1.38-2.09) and CR rates (RR 1.76, 95%CI:1.43-2.17) compared to CRT alone. The pMMR-exclusive group confirmed a significant CR (RR 1.76, 95%CI:1.3-2.37, p < 0.01) and pCR (RR 1.66, 95%CI:1.15-2.4; p < 0.01) benefit. Grade 3-4 neoadjuvant-related AEs occurred in 23% of patients, with a significant increase over CRT alone (RR 1.26, 95%CI:1.01-1.57). Surgical complications (6% overall; 4% in the pMMR-exclusive group) and ir-AEs (4% overall; 3% in the pMMR-exclusive group) were infrequent. A subgroup analysis of RCTs showed that short-course ICI containing regimen (SCRT + ICI) significantly improved pCR (RR 1.90, 95%CI: 1.36-2.65) and CR (RR 1.84, 95%CI: 1.37-2.47) over SCRT alone. However, long-course regimen (LCRT + ICI) did not show a benefit over LCRT alone (pCR: RR 1.31, 95%CI 0.94-1.81, CR: RR 1.17, 95%CI 0.53-2.59). Additionally, SCRT + ICI led to higher pooled pCR/CR rates than LCRT + ICI (CR: 59% vs. 36%, p = 0.031; pCR: 51% vs. 33%, p < 0.0001).
conclusionIn pMMR LARC, our results suggested that neoadjuvant CRT-ICI was associated with higher pCR/CR rates than CRT alone based on the analysis of available trials. This effect, however, appears confined to SCRT-ICI, with no corresponding gain seen in LCRT-ICI. Although treatment‑related toxicity is increased, severe immune‑related and surgical adverse events are infrequent. These findings suggest that selective use of CRT‑ICI may be considered, particularly when downstaging or organ preservation is a goal, but confirmatory trials and continued longitudinal follow‑up are warranted to assess response durability, survival benefits, and late toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.